Abstract Taxanes have resulted in improved survival for breast cancer patients, but often cause neurological toxicities. Identification of biomarkers related to toxicities could be important for dictating treatment regimen. We evaluated single nucleotide polymorphisms (SNPs) in the Fanconi Anemia (FA)/BRCA pathway in relation to grade 3/4 neurotoxicities in patients (n = 888) from SWOG0221, a phase III adjuvant trial for breast cancer of 4 dose/schedules of cyclophosphamide (C), doxorubicin (A), and paclitaxel (T). In a separate cohort, we measured the correlation of significant FANCD2 SNPs with corresponding gene expression. For FANCD2, permutation testing revealed that 4 (out of 20) SNPs were significantly associated with an almost two-fold increased risk of toxicity. Two FANCD2 haplotypes were also associated with neurological toxicity, with odds ratios (OR) in the overall population of 1.8 (95% confidence interval (CI) 1.3, 2.5) and 1.7 (95% CI, 1.2, 2.4). Although numbers were small, an African-American-specific haplotype was associated with an almost 3-fold increase in risk of neurologic toxicity (OR = 2.84, 95% CI = 1.2, 6.9). Expression analyses revealed that significant FANCD2 SNPs were associated with FANCD2 expression levels (P = 0.03). There were no associations between SNPs in BRCA1 and neurotoxicities. In this trial of CA?T for breast cancer, SNPs in FANCD2, but not in BRCA1, were associated with a 70-80% increase in the odds of grade 3/4 neurological toxicities and increased expression of the gene. If replicated, women with these genotypes should be closely monitored for toxicities and could be targeted
Introduction
The addition of taxanes (T) to doxorubicin (Adriamycin Ó , A) and cyclophosphamide (C) in the adjuvant setting for patients with early stage breast cancer reduces risk of recurrence and mortality. However, treatment efficacy does not come without a price [1] [2] [3] [4] [5] . Patients receiving taxanes may develop distal axonopathy with symmetrical sensory neuropathic pain and abnormal sensations such as dysesthesias, numbness, and altered proprioception. The onset is early in therapy and can last months to years in the survivorship period [6] . In a CALGB adjuvant trial of paclitaxel (C9344), 15% of patients had moderate parasthesias following treatment, and 3% had sensory neurotoxicity that interfered with daily functioning [1] Clearly, identification of biomarkers that predict taxane-induced neurotoxicity would be of value so that, balanced with efficacy, doses could be adjusted, preventive interventions could be focused, or these agents could be avoided for those at greatest risk.
The mechanisms for taxane-induced neuropathy have not been completely elucidated. Taxanes disrupt normal microtubule dynamics [7] , resulting in mitotic arrest and possibly apoptosis [8] . Emerging evidence supports a potential role of DNA damage as a means of taxane cytotoxicity. In cultured cancer cell lines, accumulated DNA breaks are observed after exposure to paclitaxel [9, 10] , and over-expression of DNA repair genes involved in chromosome instability appear to be associated with taxane resistance [11] . Thus, deficiencies in known DNA repair pathways might result in increased toxicity to taxanes. The Fanconi anemia (FA)/BRCA genes are highly polymorphic, and several studies have demonstrated that SNPs in these genes result in alterations of their enzymatic products and consequently their functions [12] [13] [14] . Thus, we evaluated associations between BRCA1 and FANCD2 SNPs with toxicities and, in another sample, examined their corresponding gene expression levels. Specifically, we tested for associations between taxane-induced neurotoxicity and SNPs in these two genes in a cohort of 888 women enrolled in an ongoing cooperative group clinical trial for breast cancer. Second, to help demonstrate biologic plausibility of SNP association signals, we evaluated the relationship of significant SNPs with expression levels in the corresponding genes using 63 human lymphoblastoid cell lines from women without a diagnosis of cancer.
Materials and methods

Patient population
We used data and samples from a North American Breast Cancer Intergroup clinical trial led by the Southwest Oncology Group (SWOG) S0221. This is a phase III trial of continuous schedule AC-paclitaxel (Taxol Ó , T) versus. Q2 week schedule AC, followed by T given either every 2 weeks or weekly for 12 weeks as post-operative adjuvant therapy. The premise of the trial is to test whether a continuous ''metronomic'' schedule is superior to an accelerated but more conventional schedule of AC-T for breast cancer.
To be eligible for the trial, patients must have nodepositive or high-risk (tumor C2 cm) node-negative operable Stage II or III invasive breast cancer with known ER/ PR status and no prior cancer, have undergone breast surgery, and have no prior chemotherapy. Blood is drawn upon registration to S0221 and shipped to the Roswell Park Cancer Institute (RPCI) laboratory, where it is processed and stored at -80°C. The total accrual goal for S0221 is 3,250 patients, and as of August 2010, 2,666 patients had been enrolled; as of early 2009, when genotyping was performed, blood was available from 905 women. The trial schema and patient numbers are presented in Fig. 1 , and methods and results are reported according to REMARK criteria [15] .
Toxicities evaluated
During the trial, toxicities are monitored and reported using the NCI Common Toxicity Criteria for Adverse Events (CTCAE) Version 3.0, which contains descriptive terminology to be used for adverse event (AE) reporting, with a grading (severity) scale provided for each AE term. Primary AEs with the taxane treatment are neurological toxicities, including pain, motor coordination difficulties, and myalgias. Grade 3 toxicities interfere with activities of daily living, and grade 4 AEs are life-threatening and often require hospitalization. In S0221, 12% of patients have experienced grade 3 or 4 neurotoxicities [1, 2] . In addition to the clinical assessment of neurotoxicities, patients are also queried at multiple time points using the Functional Assessment of Cancer Therapy-Taxane (FACT-TAX) [16] . The FACT-TAX allows us to further examine associations between genotypes and patient-reported neurologic toxicities. The Data Safety and Management Committee (DSMC) approved the analyses reported herein, and the Institutional Review Boards at Roswell Park Cancer Institute (RPCI) and all participating hospitals approved the study. S0221 is still accruing, and therefore, we cannot evaluate toxicity or genotype with cancer outcomes, or interactions of the SNPs with randomized treatment, until the primary study results are available.
SNP selection and laboratory methods
The open-source software program SNAGGER, (http:// sourceforge.net/projects/snagger), was used to select SNPs in FANCD2 and BRCA1. In addition to a minimum minor allele frequency (MAF) of 0.05 and an r 2 threshold of 0.80, we prioritized the SNP list by chromosomal position, functionality, and Illumina design scores. For the total population, 24 and 21 tag SNPs in FANCD2 and BRCA1, respectively, were selected using SNAGGER. Quality control (QC) was monitored by the inclusion of 5% blind duplicates, and concordance was 99.1%. Eight SNPs were removed from analyses due to: low MAF, violation of Hardy-Weinberg Equilibrium proportions (HWE) in those without toxicity, and genotyping quality \95%. After QC, 20 SNPs for FANCD2 and 17 SNPs for BRCA1 were evaluated among patients who self-reported as White/Other and 9 SNPs in FANCD2 and 12 in BRCA1 among AfricanAmerican (AA) women. To control for potential confounding due to cryptic population substructure, we included SNPs to estimate individual ancestry (IA), selecting 70 uncorrelated SNPs from HapMap in both Yoruban African and unrelated CEPH White populations [17] . Population admixture proportions were determined using the Bayesian clustering algorithms implemented in the program STRUCTURE v2.2 [18] .
DNA was extracted from whole blood using Qiagen Flexigene kits, according to manufacturer's instructions, and quantified using both PicoGreen and Nanodrop TM technologies. DNA was plated onto 96-well plates, and genotyping was conducted using the Illumina GoldenGate platform in the RPCI Genomics Core Facility. IA measures showed that European ancestry was estimated at 0.97 among the 740 patients who self-reported as White and 0.16 among those who self-reported as Black (n = 67). The remaining study population was primarily Asian, and average proportion of EA ancestry was 0.93; thus, these patients (n = 41) were included in analyses with women self-reporting as White. For QC, we removed individuals with [15% genotypes missing (n = 7) and patients who self-reported as Black but had more than 0.85 proportion of EA ancestry (n = 2), leaving 888 participants for analyses.
Statistical analysis
The proportion of EA admixture was included as a covariate in all models to control for potential confounding due to cryptic population substructure, as well as age and treatment group. We performed both single SNP and With available DNA and genotyping data* (n-888)
Breast Cancer Res Treat (2011) 130:993-1002 995 haplotype analyses using logistic models. For all analyses, the reference population included individuals with grades 0, 1, or 2 neurological toxicities versus grades 3/4. For single SNP tests of association, we used additive (dominant) coding for variant alleles when the prevalence of the least frequent homozygote was[0.05 (\0.05). Permutation analyses were used to account for multiple testing. This procedure preserves the correlation structure of the markers, but dissociates the relationship between the markers and toxicity grade. For each permuted data set, we performed the same regression analysis of the traits on genotypes (and haplotype) marker location, as was done for the original data, and obtained the most extreme values (positive and negative) of the test statistics. Ten thousand permutations were performed. To derive P values adjusted for multiple testing, we determined the percentage of times out of 50,000 permutations that an observed value was exceeded in the permuted data analysis. The method of Gabriel et al. [19] was used to determine haplotypes for each gene within Whites and AAs and the overall population. Each haplotype configuration, weighted by its probability, was used in the logistic regression models to test for association with grade 3/4 toxicity. To evaluate whether SNPs that were significantly associated with CTCAE grade 3/4 toxicity were also associated with self-reported toxicities, the sixteen neuropathy components of the FACT-TAX were summed [20] with a maximum score of 64 indicating no neuropathy. To be consistent with CTCAE toxicity, we categorized the neuropathy sums into tertiles, such that tertiles one and three reflected those with the least and greatest toxicities, respectively. We then used ordinal models to assess the odds of higher neuropathy compared to lower by genotype.
Ex vivo association of FANCD2 genotypes and gene expression
We evaluated whether tag SNPs in FANCD2 found to be significantly associated with risk were associated with FANCD2 gene expression; we used human lymphoblastoid cell lines from 63 unrelated European American women without a diagnosis of cancer in an independent sample [21] . Microarray-based gene expression was assayed using the Illumina HumanHT-12v3 Gene Expression Beadchip, with more than 48,000 probes derived from the National Center for Biotechnology Information Reference Sequence (NCBI) RefSeq (Build 36.2, Rel 22) and the UniGene (Build 199) databases. The raw intensity was scanned and extracted using BeadScan and the data corrected by local background subtraction in GenomeStudio module. The log 2 -transformed intensity data were normalized with the quantile normalization algorithm. FANCD2 gene was expressed in all lymphoblastoid cell lines; the expressiondetection P value was less than 0.05 across all samples. Linear regression was used to examine associations between SNPs and mean log 2 FANCD2 expression levels under dominant and additive models, adjusted for age.
Results
The characteristics of the study population in this analysis are shown in Table 1 . Approximately half of the patients were less than 51 years of age, and the majority of patients were White. According to CTC criteria, 107 (12%) patients experienced grade 3 or 4 neurotoxicity. The median FACT-TAX neurotoxicity score, reported six months after chemotherapy initiation, was 46 (range 6-64) with tertile cutpoints of 39 and 52.
Allele frequencies and HWE test P values for SNPs evaluated by toxicity status (\grade 3, grades 3/4) are shown in Table 2 . Although the minor alleles for both FANCD2 and BRCA1 did not differ by race, with the but no BRCA1 SNPS, violated HWE proportions assumption at the a = 0.05 among those experiencing toxicity, but not among those without grade 3 and 4 toxicities. The haplotype block structure for FANCD2 and associations between SNPs and toxicity are shown in Fig. 2 . While it is evident that linkage disequilibrium (LD) is strong across the entire gene, when examining the LD structure by race, populations differed, with less correlation across typed SNPs among AAs. As expected, the LD structure of BRCA1 was almost identical across populations, comprising 2 haplotypes (data not shown). We did not conduct haplotype analyses of BRCA1 with grade 3/4 neurotoxicity by race or overall due to the similar LD structure across populations and no evidence of single SNP associations at a = 0.05 (Table 3) .
For FANCD2, the four most significant single SNP associations (P \ 0.001) were found within intronic regions: rs7648104, rs7637888, rs6786638, and rs6442150, (Fig. 2a) , yielding increases in odds of neurotoxicity by 1.86 (95% CI = 1.30, 2.65), 1.87 (95% CI = 1.30, 2.67), 1.90 (95% CI = 1.32, 2.72), and 1.89 (95% CI = 1.32, 2.72), respectively. In analyses stratified by race, associations were of borderline significance in both the White/ Asian and Black populations, likely due to small numbers. When these SNPs were examined in relation to the FACT-TAX scores, ORs, although somewhat lower with slightly wider confidence intervals than when using CTC criteria, were also significantly associated with neurotoxicity when compared to women who experienced no neurotoxicity Table 4 . In the Black population, 3 haplotype blocks spanning 2 SNPS each were detected; each haplotype block consisted of 2 haplotypes with a frequency greater than 1%. The most significant 2-SNP haplotype was found at rs7648104-rs7637888, with Black women with A-G haplotype (28%) having an almost three-fold greater odds of grade 3/4 neurotoxicity (OR = 2.84, 95% CI, 1.2-6.9) than those with C-A haplotype (72%). This haplotype was less frequent (15%) in White or Asian women. Importantly, among women with grade 3 and 4 neurotoxicity, the frequency of this haplotype in White or Asian women was approximately 1/3 that of Black women (20% vs. 59%). The difference by race was much less (9%) among those who did not experience toxicity. The White and Asian population was estimated to have one haplotype block composed of two 11-SNP haplotypes and a second block spanning 8 SNPs composed of 3 haploytpes with frequency greater than 1%. Two haplotypes in each block showed an approximately 1.6-fold odds of grade 3/4 toxicity (OR = 1.6, 95% CI, 1.1, 2.4) when compared with all other haplotypes (P = 0.03). In the overall population, there was strong evidence of haplotype association with clinical neurotoxicity for the least frequent haplotype in both the first (P \ 0.005) and second (P \ 0.007) block.
FANCD2 SNP association with gene expression
A total of 4 SNPs in the intronic regions of FANCD2 were tested for association with gene expression levels of FANCD2. The first three markers are in strong LD (r 2 [ 0.99). As shown in Fig. 3 , individuals with at least one copy of the minor allele for all three SNPs have decreased FANCD2 expression and significantly different mean expression across genotypes.
Discussion
In this discovery, hypothesis-generating study, we found that patients who harbor SNPs and haplotypes in FANCD2 experienced nearly a two-fold increase in odds of grade 3 and 4 neurotoxicity compared to patients with common haplotypes. There were no associations with SNPs in BRCA1 nor were there combined effects of FANCD2 and BRCA1 genotypes (data not shown). Although numbers of Black patients were low, the frequency of ''at risk'' alleles was more common, and associations with risk of toxicity appeared to be stronger among them than among White/ Other patients. Functional analyses to examine associations between SNPs in FANCD2 and levels of gene expression showed that the ''at risk'' alleles were associated with lower gene expression. Thus, individuals with minor alleles/haplotypes may have greater odds of toxicity because FANCD2 is under-expressed, conferring insufficient activity in repairing normal neuronal or myelin sheath cells after chemotherapy-induced DNA damage.
In addition to observing associations between SNPs in FANCD2 and grades 3 and 4 toxicity according to the CTCAE reporting, we also noted relationships between these SNPs and self-reported neurotoxicities. A unique feature of this study was the ability to assess the association between these SNPS and the patients' experience of toxicity as measured by the FACT-TAX. Using these data, we found similar associations to those using CTCAE reports, adding to the validity of the results. They also demonstrate what could be interpreted as a dose-response effect. CTCAE grade 3/4 toxicity was more strongly associated with genetic variants in FANCD2. In contrast, weaker, although still statistically significant, associations were observed for lower extremes of adverse side effects.
It is well known that paclitaxel induces microtubule stabilization (MTS) and thereby mitotic arrest. However, emerging evidence supports a potential role of DNA damage following mitotic arrest in dictating taxanes' cytotoxic effects. In cultured peripheral blood lymphocytes from healthy donors, paclitaxel treatment caused significant single and double DNA strand breaks quantified by White/Other* rs3846177-rs9849434 alkaline comet assay, which was almost completely repaired after removal of the drug [9] . Similar findings were reported in cultured human cancer cells, as DNA breaks accumulated following mitotic arrest triggered by paclitaxel treatment [10] . These breaks activate a DNA damage response, which recruits DNA repair proteins and initiates DNA repair. Moreover, global gene expression analyses in cell lines in response to MTS agents, such as paclitaxel, revealed that chromosome instability determines the MTS response [11] . Failure to initiate efficient mismatch repair or homologous recombination may contribute to MTS cytotoxicity. Thus, acquired DNA damage following mitotic arrest may be one of the mechanisms responsible for taxane-caused cell death. We investigated the Fanconi anemia (FA)/BRCA pathway because of its central role in DNA damage response and mobilization of DNA repair machinery [12] [13] [14] . FANCD2 and BRCA1 co-localize to the damaged chromatin foci and may act as a platform for assembly of DNA repair machinery through crosstalk with a range of DNA repair molecules [22] . Thus, the FA/BRCA pathway may be predictive for response to cancer chemotherapy. In support of this, the FA/BRCA pathway has been linked to chemotherapy resistance in patients with glioma [19] , ovarian cancer [23] and multiple myeloma [24] , and resistance to melphalan in multiple myeloma may be circumvented by targeting this pathway with bortezomib [25] . Although there are no published studies investigating the roles of FA/BRCA pathway in MTS response, it is an important relationship to evaluate, considering the massive amount of DNA damage caused by MTS.
While the high degree of correlation among SNPs in the FANCD2 gene makes it difficult to isolate the causal variant(s) without further deep genotyping or sequencing, our observation that multiple SNPs were also associated with expression levels of FANCD2 serves to buttress the biological plausibility of the associations between these SNPs in FANCD2 and risk of neurotoxicities. When evaluating Regressing the four SNPs on expression level (adjusting for age) showed that rs9875081, rs1552244, and rs2272123 were significant at p \ 0.05; for each SNP, one additional copy of the minor allele caused a significant (P \ 0.03) decrease in FANCD2 expression levels by 0.16 (SE = 0.07). rs3172417 was not significantly associated (P = 0.56) with expression; rs9875081 and rs1552244 each explained approximately 6% of the variation in expression as measured by adjusted r 2 , and rs2272123 explained about 5% of variation in expression level haplotypes by race, the differing LD structure and higher frequency of the minor variant in the Black population yielded combinations of genetic variants with very different odds of toxicity between races. The significant two-SNP haplotype, A-G, spanning rs7648104-rs7637888, appears to be a unique race-specific risk haplotype, which could help explain the higher incidence of clinical toxicity in individuals self-reporting as Black (19%) than those self-reporting as White/Asian (9%). However, these findings must be interpreted with caution, because the sample size for Black patients is relatively small. The different LD structure of FANCD2 and the race-specific haplotype association underscores the importance of determining subgroup-specific genetic risk factors when considering genotoxic exposures.
We are unaware of any other reports of the association between SNPs in key genes involved in FA/BRCA pathway and taxane-induced neuropathy in women undergoing treatment for breast cancer in an adequately sized and welldefined population. We observed strong and significant associations between both CTC and self-reported toxicity and genetic variants in the FANCD2 gene. Furthermore, the ''risk allele'' of FANCD2 gene is associated with decreased expression of FANCD2, supporting our hypothesis that functional genetic variations in FANCD2, a key gene in FA/BRCA pathway, could modify response to taxanes. Our results must be validated in future studies and the genetic mechanisms of FA/BRCA pathway in taxane response further elucidated. Nevertheless, our findings suggest the genetic variations in FANCD2 gene could be used as an indicator for taxane toxicity, as well as a potential target for preventive measures or alternative therapeutic approaches.
